title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
3.3.3. Fruit, Vegetables, and Diet Quality | A clinically meaningful increase in the servings of fruit per day was observed in the txt4two cohort, compared with the PC cohort, 0.4 (±0.9) versus 0 (±0.9); however, this did not reach statistical significance ( | PMC9921852 | ||
3.3.4. Physical Activity | Non-significant increases in total physical activity were observed between groups over time (+45.8 min); the sample was not powered to detect statistical differences. Non-meaningful changes were observed in minutes of sedentary time and percentage of women meeting physical activity guidelines. | PMC9921852 | ||
4. Discussion | dietary behaviors | RECRUITMENT | This paper outlines the outcomes and key learnings from a pragmatic implementation of an adapted digital health program into the MMH antenatal service. The outcomes suggest that the program could feasibly be implemented with the considerable time and effort required to adapt and embed the program within the interdepend... | PMC9921852 |
Strengths and Limitations | The adaptation and testing of an effective and acceptable theoretically underpinned program that had robust formative concept testing and piloting phases was a strength of this study [ | PMC9921852 | ||
5. Conclusions | Adapting and implementing a previously tested digital intervention into a tertiary maternity hospital was feasible and elicited positive dietary quality and physical activity engagement changes. The barriers to this process included fragmented and unagile hospital and research governance and systems, while the enablers... | PMC9921852 | ||
Supplementary Materials | The following supporting information can be downloaded at: Click here for additional data file. | PMC9921852 | ||
Author Contributions | Conceptualization, S.A.W. and J.C.W.; methodology, S.A.W., B.F. and J.C.W.; formal analysis, S.A.W.; investigation, S.A.W.; data curation, S.A.W.; writing—original draft preparation, S.A.W.; writing—review and editing, S.A.W., B.F. and J.C.W.; project administration, S.A.W.; funding acquisition, S.A.W. All authors have... | PMC9921852 | ||
Institutional Review Board Statement | The study was conducted in accordance with the Declaration of Helsinki and approved by the Mater Misericordiae Ltd. Human Research Ethics Committee (HREC/MML/47416). | PMC9921852 | ||
Informed Consent Statement | Informed consent was obtained from all subjects involved in the study. | PMC9921852 | ||
Data Availability Statement | The data presented in this study are available on request from the corresponding author. The data are not publicly available, due to privacy issues. | PMC9921852 | ||
Conflicts of Interest | The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. | PMC9921852 | ||
Introduction | Diabetes | VITREOUS HEMORRHAGE, PROLIFERATIVE DIABETIC RETINOPATHY (PDR), DIABETES | Edited by: Sobha Sivaprasad, NHS Foundation Trust, United KingdomReviewed by: Yong Tao, Beijing Chaoyang Hospital, Capital Medical University, China; Xiaodong Sun, Shanghai First People's Hospital, ChinaThis article was submitted to Clinical Diabetes, a section of the journal Frontiers in Public HealthThe aim of this s... | PMC9875129 |
Methods | PDR | This study involved a prospective, randomized clinical trial. One hundred twenty-eight eyes of 128 patients of PDR who underwent pars plana vitrectomy (PPV) were enrolled. Sixty-four eyes were assigned randomly to either the IVA group (IVA injection 1 to 5 days before PPV) or the control group (no IVA injection). The p... | PMC9875129 | |
Results | The VH incidences in the IVA group and the control group were 14.8 and 39.3% at week 1, 8.6 and 31.7% at month 1, 11.7 and 30.5% at month 2, and 8.6 and 30.5% at month 3, respectively. Intergroup differences showed a significantly decreased VH rate in the IVA group compared with that in the control group at week 1, mon... | PMC9875129 | ||
Conclusions | PDR | This study found that the adjunctive use of preoperative IVA reduces early and late postoperative VH in vitrectomy for PDR. | PMC9875129 | |
Introduction | diabetic retinopathy, TRD, PDR, Diabetic retinopathy, tractional retinal detachment, vitreous hemorrhage, vision loss, diabetes | DIABETIC RETINOPATHY, TRACTIONAL RETINAL DETACHMENT, DIABETIC RETINOPATHY, POSTOPERATIVE COMPLICATIONS, RETINA, PROLIFERATIVE DIABETIC RETINOPATHY (PDR), VITREOUS HEMORRHAGE, COMPLICATIONS, DIABETES | Patients with diabetic retinopathy (DR) are becoming more and more predominant in many countries with the increasing prevalence of diabetes worldwide. Diabetic retinopathy is the leading cause of vision loss in patients with diabetes. The standard and effective surgical treatment for vitreous hemorrhage (VH) and tracti... | PMC9875129 |
Methods | PDR, myocardial infarction, liver or kidney dysfunction, diabetes mellitus, tractional retinal detachment, Diabetic Retinopathy, tamponade, postvitrectomy, choroidal or retinal disease, cerebrovascular accident, IOL, hypertension, T2DM, coagulation mechanism disorder | SYSTEMIC DISEASE, DIABETES MELLITUS, RETINAL TEAR, DIABETIC RETINOPATHY, EVENTS, INTRAOPERATIVE BLEEDING, POSTOPERATIVE COMPLICATIONS, PROLIFERATION, EYE, TRACTIONAL RETINAL DETACHMENT, IOL, LENS, TYPE 2 DIABETES MELLITUS, COMPLICATIONS, INTRAOCULAR PRESSURE, MYOCARDIAL INFARCTION, CEREBROVASCULAR ACCIDENT, NEOVASCULAR... | This was a prospective, randomized clinical trial (NCT 05478967). The study followed the tenets of the Declaration of Helsinki and was approved by the Institutional Review Board of the Peking University People's Hospital. Written informed consent was signed by all participants before enrollment.The present study enroll... | PMC9875129 |
Results | vitreous hemorrhage, TRD, NVG, fifty-four | VITREOUS HEMORRHAGE, NEOVASCULAR GLAUCOMA, ENDOPHTHALMITIS, VITREOUS HEMORRHAGE, RESOLUTION | One hundred fifty-four eyes were enrolled in the study and allocated randomly into two groups: 78 eyes in the IVA group and 76 eyes in the control group. During follow-up, 26 eyes were excluded: 16 cases because of the loss of follow-up and 10 eyes because of the administration of intravitreal silicone oil injection. F... | PMC9875129 |
Discussion | PDR, TRD, Diabetic retinopathy, blindness, ischemia, tamponade | DIABETIC RETINOPATHY, BLINDNESS, ISCHEMIA, COMPLICATION, BLIND, NEOVASCULARIZATION, SCLERA, REGRESSION | Diabetic retinopathy (DR) is one of the leading causes of being legally blind in working-aged people and is responsible for up to 4.8% of blindness worldwide. Although PPV was the standard management for PDR with VH or TRD, they may suffer from postoperative VH. This complication will hinder fundus monitoring and/or ad... | PMC9875129 |
Data availability statement | The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation. | PMC9875129 | ||
Ethics statement | The studies involving human participants were reviewed and approved by Institutional Review Board of People's Hospital of Peking University. The patients/participants provided their written informed consent to participate in this study. | PMC9875129 | ||
Author contributions | JQ and XL contributed to the interpretation of the data. The first draft of the manuscript was written by JQ and all authors commented on previous versions of the manuscript. All authors contributed to the study's conception and design. All authors read and approved the final manuscript. | PMC9875129 | ||
Conflict of interest | The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. | PMC9875129 | ||
Publisher's note | All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or ... | PMC9875129 | ||
References | PMC9875129 | |||
Aims | cord injury | KCL‐286 is an orally available agonist that activates the retinoic acid receptor (RAR) β2, a transcription factor which stimulates axonal outgrowth. The investigational medicinal product is being developed for treatment of spinal cord injury (SCI). This adaptive dose escalation study evaluated the tolerability, safety ... | PMC10835503 | |
Methods | BLIND | The design was a double blind, randomized, placebo‐controlled dose escalation study in 2 parts: a single ascending dose adaptive design with a food interaction arm, and a multiple ascending dose design. RARβ2 mRNA expression was evaluated in white blood cells. | PMC10835503 | |
Results | rash | ADVERSE EVENTS, EYE DISORDERS | At the highest single and multiple ascending doses (100 mg), no trends or clinically important differences were noted in the incidence or intensity of adverse events (AEs), serious AEs or other safety assessments with none leading to withdrawal from the study. The AEs were dry skin, rash, skin exfoliation, raised liver... | PMC10835503 |
Conclusion | KCL‐286 was well tolerated by healthy human participants following doses that exceeded potentially clinically relevant plasma exposures based on preclinical in vivo models. Target engagement shows the drug candidate activates its receptor. These findings support further development of KCL‐286 as a novel oral treatment ... | PMC10835503 | ||
What is already known about this subject | injuries | SCAR |
Retinoic acid receptor (RAR) β signalling is involved in central nervous system (CNS) regeneration.RARβ is a neuronal transcription factor that regulates numerous pathways in CNS regeneration; these include, axonal outgrowth, synaptogenesis, modulation of the glial scar and axonal pathfinding.KCL‐286 is a preclinical ... | PMC10835503 |
What this study adds | nerve injuries, cord injury |
KCL‐286 was tested in healthy male adults to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of this agent under investigation for the treatment of spinal cord injury.Safety and pharmacokinetic data indicate that KCL‐286 is well tolerated at a 100‐mg daily dose, which equates to a dose shown ... | PMC10835503 | |
INTRODUCTION | RA, cord injury, road accidents | The reported global prevalence of spinal cord injury (SCI) is between 0.7 and 1.2 million incident cases per year with falls and road accidents being the major causes.The retinoic acid (RA) signalling pathway has been shown to be involved in axonal outgrowth. The pathway consists of the nuclear receptors, the RA recept... | PMC10835503 | |
MATERIAL AND METHODS | PMC10835503 | |||
Study oversight | PD, SAD | BLIND | The present study is a phase 1, first‐in‐human double blind, randomized, placebo‐controlled trial, in male healthy volunteers, consisting of a single ascending dose (SAD) adaptive design with a food interaction (FI) arm, and a multiple ascending dose (MAD) design, to evaluate the safety, tolerability, PK and pharmacody... | PMC10835503 |
Study design | SAD | SECONDARY, BLIND | This was a prospective, Phase I, double blind, randomized, placebo controlled, dose escalating study conducted at 2 sites. The study comprised 2 parts: Part A included SAD in 8 cohorts (S1 to S8) with a food interaction (FI) arm of 1 cohort and Part B MAD in 5 cohorts (M1 to M5) in which the volunteers were dosed once ... | PMC10835503 |
Study participants | Healthy adult males aged between 19 and 45 years were randomized into the trial. Female volunteers were excluded from this study as at that time reproductive toxicology data were not complete in female models. Participants had a body mass index ≥18 and ≤30 kg/m | PMC10835503 | ||
Sample collection and analysis | BLOOD | Blood and urine samples for PK analysis were collected from the individuals in all groups within 2 h before dosing and at 0.5, 1 1.25, 1.5, 2, 3, 5, 8, 12, 24, 36 and 48 h after dosing. Venous blood samples were collected in heparin treated tubes, and centrifuged within 30 min (400 × g, 4°C, 10 min). The upper plasma l... | PMC10835503 | |
PK assessments | PMC10835503 | |||
Determination of drug concentrations and dose proportionality | Plasma and urine PK parameters of KCL‐286 were analysed using noncompartmental analysis. Actual dosing and PK sampling times were used for PK parameters. Linear log trapezoidal method (linear on ascending and log on descending concentrations) was used to integrate the plasma concentration time profiles out to the time ... | PMC10835503 | ||
Starting dose and escalation decisions | Safety results and limitations imposed by the protocol were the primary consideration when deciding on the starting dose and subsequent dose for the next cohort. To calculate the starting dose, the no‐observed‐adverse‐effect level from Day‐28 dog toxicokinetic study was used for planned ceiling exposure and dose level.... | PMC10835503 | ||
Statistical methods | The data processing and statistical analysis of the results were performed by Richmond Pharmacology Limited. The PK parameters were computed using WinNonlin™ PK software (version 6.3 or higher Pharsight Corp, Sunnyvale, CA, USA). All other analyses were conducted using SAS PC Version 9.4 or later (SAS Institute, NC, US... | PMC10835503 | ||
Nomenclature of targets and ligands | Key protein targets and ligands in this article are hyperlinked to corresponding entries in | PMC10835503 | ||
RESULTS | PMC10835503 | |||
Subjects | SAD | A total of 109 healthy male participants took part in the study. The SAD substudy comprised 56 randomized participants: 42 participants across the single dose KCL‐286 treatment arms and 14 participants in the placebo arm. Across the cohorts, participants randomized to KCL‐286 included 3 to 1 mg, 4 to 2 mg, 5 to 48 mg a... | PMC10835503 | |
SAD | SAD | Plasma concentration–time profiles overlaid for each dose group in the SAD (linear) are in Figure Overlaid mean plasma KCL‐286 concentration Summary of pharmacokinetic parameters at Day 1 (PK set)—single ascending dose.Abbreviations: Ae, KCL‐286 excreted unchanged in a collection period; AeData show mean and standard d... | PMC10835503 | |
MAD | Plasma concentration–time profiles overlaid for each dose group of the MAD cohorts are in Figure Overlaid mean plasma KCL‐286 concentration Summary of pharmacokinetic parameters (PK set)—multiple ascending dose.Abbreviations: Ae, KCL‐286 excreted unchanged in a collection period; AeData show mean and standard deviation... | PMC10835503 | ||
Food effect | Plasma concentration–time profiles and plasma PK parameters following single oral doses of 6 mg KCL‐286 in fasted and fed participants are shown in Figure Summary of overall pharmacokinetic parameters (PK set)—food interaction.Abbreviations: Ae, KCL‐286 excreted unchanged in a collection period; AeData show mean and st... | PMC10835503 | ||
Assessment of dose proportionality | PMC10835503 | |||
SAD (includes 6‐mg dose from the food interaction substudy) | Increase in mean plasma exposure was between proportional and subproportional with dose in terms of mean CFor the 6‐mg fasted dose from the FI substudy, dose‐proportionality exposure increase was within 2‐fold of the nominal dose increment, and was considered to be effectively dose proportional and within normal variab... | PMC10835503 | ||
MAD | For the MAD cohorts, across the entire dose range steady‐state concentration was achieved from Day 3 or earlier at predose. Low concentrations of KCL‐286 were detected around 1 ng/mL from 36 or 48 h postdose through to the follow‐up time (nominally 168 h after dose 7). Over the entire dose range investigated there was ... | PMC10835503 | ||
Urine: All parts of the study | The amount of drug secreted in urine was proportional to the dose administered throughout all participants of the study (Tables | PMC10835503 | ||
PD results | PMC10835503 | |||
Exploratory biomarker for target engagement | RARβ2 was not detected in WBCs isolated from plasma from placebo samples or the 1‐ and 12‐mg dosed MAD cohorts. In the MAD cohorts of 24, 75 and 100 mg dosing, RARβ2 expression upon ligand binding becomes upregulated and measurable (Figure Expression of retinoic acid receptor (RAR)β2 in white blood cells in multiple as... | PMC10835503 | ||
Safety evaluation | dry skin, epistaxis, stomatitis, abnormal dreams, TEAEs, pain, dizziness, nasal congestion, headache, paraesthesia, dysgeusia, TEAE, SAD | STOMATITIS, MEDICAL DEVICE SITE IRRITATION, EVENT, HYPERBILIRUBINAEMIA, DRY EYE, OCULAR HYPERAEMIA, PARAESTHESIA, EPISTAXIS, EVENTS, INJECTION SITE BRUISING, HYPERTRIGLYCERIDAEMIA | An overview of treatment‐emergent AEs (TEAEs) is provided for SAD in Table Across the SAD substudy, 56 TEAEs were reported by 31/56 (55.4%) participants. No dose relationship for any TEAE was evident. The most common TEAEs reported in the KCL‐286 treated participants included abnormal dreams (3 participants), skin exfo... | PMC10835503 |
DISCUSSION | nerve injuries, dry irritated, axonal regenerationThe TEAEs, SAD | MINOR | The treatment of nerve injuries including SCI is a major unmet clinical need as there are no therapies that can lead to axonal regeneration and functional recovery. RARβ2 activation is an attractive target to treat an SCI, as it is a neuronal located transcription factor that has multiple effects on pathways involved i... | PMC10835503 |
CONCLUSIONS | PD, injuries, SCIs | This study has demonstrated that KCL‐286 an orally available RARβ agonist, engages its receptor, and the safety, tolerability, PK and PD data support the use of up to 100 mg daily in fed conditions for future clinical studies in SCIs and other CNS injuries where axonal regeneration is required. | PMC10835503 | |
AUTHOR CONTRIBUTIONS | P. | Jonathan P. T. Corcoran, Maria B. Goncalves, Adrian P. Mander, Tim Mant, Jane Holmes, Daryl Bendel, Jörg Täubel, John Posner, Henry Fok and Hana Hassanin made substantial contributions to the conception and design of the work and the analysis and interpretation of the data as well as drafting and revising the work. E.C... | PMC10835503 | |
CONFLICT OF INTEREST STATEMENT | The authors declare no competing financial interests. MBG and J.P.T.C have a matter of composition patent for KCL‐286. | PMC10835503 | ||
Supporting information |
Click here for additional data file. | PMC10835503 | ||
ACKNOWLEDGMENTS | We thank the NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, for their support. | PMC10835503 | ||
DATA AVAILABILITY STATEMENT | The data in this article belong to the sponsor. The data may be made available to readers with permission from the corresponding author and sponsor. | PMC10835503 | ||
REFERENCES | PMC10835503 | |||
Background | hepatitis B | HEPATITIS B, VIRUS, CHRONIC HEPATITIS, HEPATITIS D | The geographical distribution of hepatitis B virus (HBV) and hepatitis D virus (HDV) genotypes is uneven and has its own clinical and organizational implications for health systems. Despite the introduction of vaccination and successful antiviral therapy the prevalence of chronic hepatitis B (with or without delta agen... | PMC10426108 |
Methods | CHRONIC HEPATITIS | Total 834 chronic hepatitis B (with or without delta agent) patients were included to the study from November 2017 to June 2019. The material was collected from the regional hepatological сenters from 13 cities of Kazakhstan. Genotyping of HBV/HDV isolates was carried out using phylogenetic analysis of null-binary sequ... | PMC10426108 | |
Results | Overall 341 samples were PCR-positive and genotyped for HBV. Comparison and phylogenetic analysis of nucleotide sequences of HBV isolates showed that they were represented by genotypes HBV-D (95.9%), HBV-A (3.5%) and HBV-C (0.6%). At the same time, the identity of the nucleotide sequences of Kazakhstani isolates were: ... | PMC10426108 | ||
Conclusion | CHRONIC HEPATITIS | This study describes for the first time the molecular epidemiology of HBV and HDV in Kazakhstan. The data obtained expand the knowledge of the global epidemiology of viruses; have potential implications for public health policy and for further clinical research on chronic hepatitis in Kazakhstan. | PMC10426108 | |
Trial registration | ClinicalTrials.gov NCT05095181 (registered on 27/10/2021). | PMC10426108 | ||
Supplementary Information | The online version contains supplementary material available at 10.1186/s12879-023-08524-1. | PMC10426108 | ||
Keywords | PMC10426108 | |||
Introduction | hepatitis B infection, cirrhosis, Cirrhosis, HBV infection | CIRRHOSIS, INFECTION, HEPATITIS B INFECTION, CIRRHOSIS, SUPERINFECTION, DISEASES | The burden of hepatitis B infection is highest in the WHO Western Pacific Region and the WHO African Region, where 116 million and 81 million people, respectively, are chronically infected. Sixty million people are infected in the WHO Eastern Mediterranean Region, 18 million in the WHO South-East Asia Region, 14 millio... | PMC10426108 |
Materials and methods | PMC10426108 | |||
Study population | chronic hepatitis B | The study involved 834 adults with chronic hepatitis B (the presence of HBsAg in the blood or serum for more than 6 months), who were treated in regional hepatological centers during the November 2017 to June 2019 in 13 cities of Kazakhstan. | PMC10426108 | |
Ethics statement | Study was approved by the institutional review board of Local Ethical Committee of the National Scientific Center of Surgery named after A.N. Syzganov (Almaty, Kazakhstan) on 14 September 2017. Informed written consent was obtained after detailed explanation of the study at the time of sampling from all participants. | PMC10426108 | ||
Serological analysis | HbsAg (Abbott ARCHITECT | PMC10426108 | ||
DNA isolation | -20 | Venous blood from HBV and HDV positive patients were used for studies. HBV DNA and HDV RNA were isolated using the GeneJET Viral DNA/RNA Purification Kit (Thermo Fisher Scientific™, USA) according to the manufacturer’s instructions. 200 µl of venous blood with EDTA was used for isolation. cDNA from RNA was obtained usi... | PMC10426108 | |
PCR for DNA amplification | SEPARATION, AMPLIFICATION, POSITIVE | PCR was performed using a set of specific primers proposed by Sitnik et al. (2004) for HBV and Shahinsaz et al. (Shahinsaz et al., 2006) for HDV, the characteristics of which presented in Tables S1 and S2 [In the absence of a PCR product of a given size, a second round of PCR was performed with nested primers and under... | PMC10426108 | |
Sequencing of PCR products and nucleotide sequence analysis of HBV and HDV | SEPARATION | Before sequencing, PCR products of HBV/HDV were purified from primer and nucleotide residues using ExoSAP-IT™ PCR Product Cleanup Reagent (Applied Biosystems™, USA) according to the manufacturer’s instructions. The purified PCR products were sequenced in two directions, using a forward and reverse FHBS1-RHBS1 or FHBS2-... | PMC10426108 | |
Genotyping and HBV/HDV reference sequences | Verification of HBV DNA and HDV RNA sequences was carried out using the Nucleotide BLAST application as well as using the Genotyping (HBV) application [Genotyping of HBV/HDV isolates was carried out using phylogenetic analysis of null-binary sequences of Kazakhstani isolates, in comparison with the reference sequences ... | PMC10426108 | ||
Results | Among 834 patients registered in hepatological centers of the Republic of Kazakhstan, 487 samples were positive for HBsAg at the time of the study, among which 341 were PCR-positive for HBV and genotyped. Among 487 HBsAg-positive samples, 261 samples were also positive for HDAg, while 256 were PCR-positive for HDV and ... | PMC10426108 | ||
Hepatitis B virus genotyping results | hepatitis B, ’ blood | HEPATITIS B, VIRUS | Patients’ blood (487 samples in total) positive for HBsAg were obtained from the following regions of the Republic of Kazakhstan: Aktau, Atyrau, Oskemen, Turkestan, Taraz, Chimkent, Almaty, Astana, Kyzylorda, Pavlodar, Aktobe, Kostanay and Karaganda.In total, out of 487 samples, 341 samples were positive for PCR and ge... | PMC10426108 |
The result of a study of hepatitis D virus genotypes | VIRUS | Patient blood (261 samples) positive for HBsAg and anti-HDVAg ELISA were received from the following regions: Taraz, Chimkent, Almaty and Almaty region, Kyzyl-Orda, Pavlodar, Aktobe, Oskemen, Aktau, Atyrau, South Kazakhstan region.In total, out of 261 samples, 256 samples (98%) were PCR positive and genotyped. Comparis... | PMC10426108 | |
Discussion | HDV | This study described for the first time the molecular (genetic) epidemiology of hepatitis B and hepatitis Delta viruses in Kazakhstan. A total sample of 341 people with HBV and 256 people with HDV were genotyped.The most common HBV genotype was the D genotype (95.9%), specifically subgenotype D1 (61.5%) in Kazakhstan. ... | PMC10426108 | |
Conclusion | Current study was the first to describe the molecular epidemiology of HBV and HDV in Kazakhstan. The genotype D (namely, the D1 subgenotype) of the HBV was predominant, and in all cases, the genotype 1 of the HDV was identified. The data obtained expand the knowledge of the global epidemiology of HBV and HDV and have c... | PMC10426108 | ||
Acknowledgements | The authors thank the administration of the regional hepatological centers of Kazakhstan for their support in conducting the study. | PMC10426108 | ||
Author contributions | Conceptualization and Methodology: B.I.; Investigation and Data curation: B.A., K.Sh., G.A., and G.I.; Genetic testing: V.B., M.S., D.M., J.G., and I.S.; Formal analysis: D.S.; Writing - original draft preparation: B.I., B.A., and B.B.; Writing - review and editing: B.I. and A.B.; Funding acquisition: B.I.; Supervision... | PMC10426108 | ||
Funding | This research was funded by the Ministry of Healthcare of the Republic of Kazakhstan, grant number OR12165486 “National Programme for the Introduction of Personalized and Preventive Medicine in The Republic of Kazakhstan (2021–2023)” (Grant number OR12165486, registration number 0119РКИ0356). | PMC10426108 | ||
Data Availability | All data available by request to corresponding author. | PMC10426108 | ||
Declarations | PMC10426108 | |||
Ethics approval and consent to participate | This study is being carried out in accordance with relevant guidelines and regulations. All participants had given written informed consent to one of the study investigators in accordance with the Declaration of Helsinki. Study was approved by the institutional review board of Local Ethical Committee of the National Sc... | PMC10426108 | ||
Consent for publication | Not applicable. | PMC10426108 | ||
Clinical trial registration | ClinicalTrials.gov NCT05095181 (registered on 27/10/2021). | PMC10426108 | ||
Competing interests | The authors declare that they have no competing interests. | PMC10426108 | ||
List of abbreviations | hepatitis B, Hepatitis B virusHepatitis D | HEPATITIS B | Hepatitis B virusHepatitis D virusWorld Health OrganizationChronic hepatitis B | PMC10426108 |
References | PMC10426108 | |||
Objectives | SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | To explore the feasibility and effectiveness of telehealth-supervised exercise for adults with Systemic lupus erythematosus (SLE). | PMC9944478 | |
Methods | fatigue, pain | This was a non-randomised controlled pilot trial comparing telehealth-supervised exercise (8 weeks, 2 days/week, 45 min, moderate intensity) plus usual care with usual care alone. Mixed methods were used to assess change in fatigue (FACIT-fatigue), quality of life (SF36), resting fatigue and pain (11-point scale), lowe... | PMC9944478 | |
Results | Fifteen female adults with SLE were included (control group | PMC9944478 | ||
Conclusion | Key findings from this mixed-method investigation suggest that telehealth-supervised exercise was feasible for, and well-accepted by, adults with SLE and resulted in some modest health improvements. We recommend a follow-up RCT with more SLE participants. | PMC9944478 | ||
Introduction | chronic, multisystem, autoimmune disease | CARDIOPULMONARY DISEASES, AUTOIMMUNE DISEASE, SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease characterised by an immune response to self-antigens.Telehealth is a possible strategy for delivering exercise interventions for people with SLE that may alleviate some of the reported barriers (i.e. exercise performed in the comfort of th... | PMC9944478 |
Methods | PMC9944478 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.